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In designing HIV protease inhibitors as potential drugs for AIDS therapy, knowledge about 
what peptide sequences in polyproteins are cleavable by HIV proteases is very useful. In this 
article, based on the formulation that any octapeptide can be uniquely expressed as a 160- 
dimensional vector and the principle that the similarity of any two such vectors is associated 
with their correlation angle, a new method is proposed to predict the cleavability of a peptide 
sequence by HIV-1 and HIV-2 proteases. The average predicted accuracy the new method 
for the 105 peptide sequences whose cleavability by HIV-1 protease is known is 96/105 = 
9.14%, which is about 8% higher than that by the existing method for the same set of data. 
A considerably high rate of correct prediction was also obtained when the new method was used 
to predict the HIV-2 protease-cleaved sites in some proteins. 
KEY WORDS: HIV-1 protease; HIV-2 protease; specificity; 160-D space; normal distribution. 
1. INTRODUCTION 
Since the discovery of the disease a decade ago, 
acquired immunodeficiency syndrome (AIDS) has 
become a synonym of terror. The magnitude of the 
mounting AIDS problem is sobering. Since the initial 
clinical reports in 1981, over 210,000 cases of  AIDS 
have been diagnosed in the United States, and nearly 
half of these patients have died as a result of the 
disease. Globally, the World Health Organization 
estimates that 6-8 million people, or perhaps as many 
as 1 in every 400 adults, are currently infected with 
HIV. A new report on AIDS by the World Health 
Organization predicts a far grimmer future than pre- 
viously forecast, warning that more than 100 million 
people worldwide could be infected by the end of the 
decade. As claimed by some experts, "AIDS is a global 
epidemic that is heading out of  control." AIDS has 
galvanized the concern and efforts of physicians, 
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scientists, and even the lay public alike. Actually, it 
has presented to scientists of all areas a significant 
challenge (i.e., how to provide any useful knowledge 
and technology at all that will lead to finding effective 
drugs against AIDS). 
It has been clearly identified that human immu- 
nodeficiency virus (HIV) is the primary cause of 
AIDS (Barr6-Sinoussi et  al., 1983; Gallo et  al., 1984). 
Therefore, a key step against AIDS is how to suppress 
HIV. It has been known that the replication of  HIV 
is accompanied by the process in which some high 
molecular weight polyproteins are cleaved by a speci- 
fic enzyme called HIV protease. This processing is 
indispensable to the viral reproduction (Kohl et  al., 
1988; Hellen et  al., 1989; Wlodawer et  al., 1989). 
Therefore, one of  the effective avenues in suppressing 
the growth of HIV is to inhibit the HIV protease. 
Many efforts have been made in order to find specific 
inhibitors to inactivate HIV-protease (Putney, 1992). 
In this regard, information about the HIV protease 
cleavage sites in polyproteins is very useful in refining 
our understanding of the specificity. Moreover, the 
knowledge thus acquired can play a guiding role for 
designing HIV protease inhibitors as potential drugs 
0277-8033/93/0600-0291507.00/0 © 1993 Plenum Publishing Corporation 
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for AIDS therapy (Hellen et  al., 1989; Henderson 
et  al., 1988). Consequently, it is very useful to develop 
a method to predict the cleavability of a peptide 
sequence by HIV protease. 
Recently, based on a series of sequences sur- 
rounding HIV protease cleavage sites in proteins, a 
cumulative specificity model was proposed (Poorman 
et  al., 1991) to characterize the substrate specificity of 
HIV protease. According to their model, the moiety 
of susceptible sites in polyproteins is usually an octa- 
peptide, although it may occasionally be a heptapep- 
tide. Furthermore, if the positions of the eight amino 
acids of an octapeptide are subsequently expressed as 
P4, P3, P2, P1, Pv, Pz, Py, P4', then the bond to be 
cleaved by the enzyme, the so-called scissile bond, is 
the one between P1 and Pv. According to their model, 
an octapeptide is characterized by an h function, 
which is actually a multiplication of some parameters 
derived from a set of peptides known cleavable by 
HIV protease. The prediction of cleavability for a 
given peptide is based on the following criterion: if its 
h value is greater than h*, the so-called "cutoff" value 
or critical value, the peptide is assumed to be cleavable 
by HIV protease; otherwise, it is not. Accordingly, 
their method can also be termed as h function method. 
For the case of HIV-1 protease, according to their 
report, the rate of correct prediction for 74 Therefore, 
one of the effective avenues in suppressing the growth 
of HIV is to inhibit the HIV protease. Many efforts 
have been made in order to find specific inhibitors to 
inactivate HIV-protease (Putney, 1992). In this regard, 
information about the HIV protease cleavage sites in 
polyproteins is very useful in refining our understand- 
ing of the specificity. Moreover, the knowledge thus 
acquired can play a guiding role for designing HIV 
protease inhibitors as potential drugs for AIDS therapy 
(Henderson et  al., 1988; Hellen et  al., 1989). Conse- 
quently, it is very useful to develop a method to 
predict the cleavability of a peptide sequence by HIV 
protease. 
2. METHOD 
Any octapeptide x can be expressed as 
x ¢:I> X4 X3 X2 Xl Xl, X2, X3. X 4 , (1) 
where Xi (i = 4, 3, 2, 1, 1', 2', 3', 4') represent the 
amino acid occupying subsite Pi. Since each of its 
eight subsites can be occupied by any of 20 amino 
acids, the octapeptide x can be uniquely defined as a 
20 x 8 = 160-D (-dimensional) vector, as formulated 
as follows: 
, (~4(x) . . . . . .  • ( x ) = { . . .  ' • (~3 (X), , ,  ( ~  (X), 
• . . ,  q~ (X) . . . . .  q~il'(X) . . . . .  q~i'(X), 
. . . .  . . . , ¢ i ,  ( x ) ,  . . . } 
( i = 1 , 2 , . . . , 2 0 )  (2) 
where 4~(x) = 1 if position P4 is occupied by the ith 
amino acid, otherwise ¢~(x) = 0, and so forth. Here, 
the amino acids are numbered according to the 
alphabetic order of their one-letter code--that  is, i = 
1, 2 , . . . ,  20 for A (alanine), C (cysteine) . . . . .  Y 
(tyrosine), respectively. For example, if an octapeptide 
x = ACACYYYY, then its characteristic vector in the 









0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,1 
Occasionally, one has to deal with heptapeptides in 
which the position P4 or P4' is not occupied by any 
amino acid (Poorman et  al., 1991). For cases like 
that, just put q~(x) = 0 or q~,(x) = 0 for all of i = 
1, 2, . . .  , 20, and all the formulation described here 
is valid for hepaptides as well. On the other hand, the 
norm of the cleavable peptide sequences by HIV-1 
protease can also be defined in the same 160-D space, 
as given by 
= • . ,  q~4(H-1), . . . ,  ~b3(S-1 ) . . . . .  
. . . .  (~'1 (H- 1) . . . . .  ( ~ . ( H -  I) . . . . .  q~, (H-1) ,  
. . . .  q~.(H-1)  . . . . .  q~],(H-1) . . . .  } (4)  
where H- 1 represents the norm of octapeptides cleav- 
able by HIV-1 protease and its components in the 
160-D space are given by 
(b}(H-1) = p~:(H-1) - -  # i  
( 5 )  
( i =  1 , 2 , . . . , 2 0 ; j = 4 , 3 , . . . , 3 ' , 4 ' )  
where p~(H-1) is the frequency of amino acid i occur- 
ring in the position Pj as will be derived later from a 
training set consisting of cleavable oligopeptides by 
HIV-1 protease, and pi the abundance of amino acid 
i in globular proteins (Nakashima et  al., 1986). 
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The components thus defined for the norm 
ql(n-1) are justifed by the fact that if amino acid i in 
position Pj is critical to the cleavage specificity, its 
frequency pj(H-1) in ~li(i-i-1) should be significantly 
greater than its abundance, //, in globular proteins, 
and hence the corresponding component q$j(H-1) is 
positive. If amino acid i in position Pj plays an unfa- 
vorable or immaterial role to the specificity, then the 
corresponding component qSj(H-1) would become 
negative or zero, respectively. Therefore, unlike Eq. 
(3) which represents a clear-cut octapeptide in the 
160-D space as reflected by either 0 or 1 in its compo- 
nents, the HIV-1 norm as defined by Eqs. (4) and (5) 
reflects the composition probabilities of various 
cleavable peptides. 
Similarly, the standard vector representing the 
norm of peptide sequences cleavable by HIV-2 prote- 
ase can be expressed by 
I l l(H-2) : { . . . ,  q~(H-2)  . . . .  , q~ (H-2 )  . . . . .  q ~ ( . - 2 ) ,  
4 il (I-I-2), . . . .  . . ~ , ( H - 2 ) ,  • ,  ~ l , (H-2) ,  . . • , 
. . . .  4 @ ( " - 2 ) ,  . , . , q~, (H-Z) . . . .  } (6)  
where H-2 represents the norm of octapeptides cleav- 
able by HIV-2 protease and its components in the 
160-D space are given by 
qb}(H-2) = p j (H-2)  - -  #i 
( i =  1,2 . . . .  , 2 0 ; j = 4 , 3  . . . .  , 3 ' , 4 ' )  
(7) 
where pj(n-2) is the frequency of amino acid i occur- 
ring in the position P~ for the norm of peptides cleav- 
able by HIV-2 protease. 
According to the Cauchy-Schwartz-Buniakow- 
sky inequality, for any two arbitrary sets of numbers 
ai, a2, • . • , a~ and bl, b2 . . . . .  b~, we have 
(k~, akbkt2~ f21 a 2) (k~l b2) (8) 
The equality holds if, and only if, the sequences a~, a2, 
. . . .  a. and b~, b2 . . . . .  bn are proportional. Thus, the 
correlation angles of the vector qi(x) with q~(n-1) and 
qll(n-2) can be defined as follows: 
~" re(x)- *(--0 } 
OH_ , (X) : COS -1 ~ I~---(~)1 ] *(~-1)1 
{ (II(X) " (101(n-2) } 
(9) 
o r  
0..~ (x) 
f 4 20 i i _2_;=, 2 i, 'c 
COS-I [ 4 20 i 2 4 20 i 2 ,/2 
: ]} J 
O..2(x) 
f 4 20 i i 2 Z:.E,:, < ( x ) < ( . -  ) 7, COS 
{[~=1ET0= i +}(X)2][E~= i ET0= i (~j(H_2)2]} ,/2 J 
(10) 
where ®H-1 (X) is the correlation angle of the vector 
eli(x) for the octapeptide x with the standard vector 
~ll(n-1) representing the norm of peptide sequences 
cleavable by HIV-1 protease, and ®H-2 (X) is the corre- 
lation angle of the vector cIl(x) with the vector ~(n-2) 
representing the norm of peptide sequences cleavable 
by HIV-2 protease. Define 
A O H . i ( X )  i 0 " . , -  OH-, (X) (1 l )  
AO..dx)  = 0 %  - O . .dx)  
where the parameters O*.1 and 0*.2 are the upper 
limits of correlation angle for the peptide sequences 
cleavable by HIV-1 and HIV-2 proteases, respectively, 
and they can be determined through an optimization 
procedure as will be illustrated later. 
Thus, whether an octapeptide x can be cleaved by 
HIV-I or HIV-2 protease will depend on the value of 
On-1 (x) o r  ®H.2(X), as can be formulated by the follow- 
ing eqs. (12) and (13): 
f 
An octapeptide x can be 
cleaved by HIV-1 protease, if AOHu (x) _> 0 
(12) 
j An octapeptide x cannot be 
t, cleaved by HIV-1 protease, ifA®H.,(x) < 0 
I An octapeptide x can be 
cleaved by HIV-2 protease, if A®H.2(x) > 0 
(13) 
An octapeptide x cannot be 
cleaved by HIV-2 protease, if A®n.2(x ) < 0 
The physical implication of Eqs. (12) and (13) can 
be further illustrated as follows. As is well known, the 
smaller the projection angle between two vectors, t h e  
larger their mutual projection, and hence the stronger 
their similarity. Thus, the vector ~ll(x) with 
AOn.,(x) _> 0 (or AOH.2(X ) > 0) is closer to the norm 
of the cleavable peptides than the vector II)(x) with 
A®n.l(x) < 0 (or A®H_2(X) < 0), and hence is more 
likely to be cleavable by HIV-1 (or HIV-2) protease. 
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In other words, the current approach provides a quan- 
titative description for the similarity between any 
given peptide sequence and the standard cleavable 
peptide in terms of the corresponding projection angle 
as defined in Eq. (10). 
It  should be pointed out that this method, like the 
h function method, depends on the independent- 
subsite specificity assumption (i.e., the "best"  amino 
acid at position P~ is completely independent of  amino 
acid present at P2 and Pv). In many  cases this is a valid 
first approximation according to Schechter and Berger 
(1967). 
3. R E S U L T S  A N D  D I S C U S S I O N  
According to Eqs. (12) and (13), to judge 
whether a peptide x can be cleaved by HIV-  1 or HIV-2 
protease, we have to first calculate O..l  (x) or ®H.2(x), 
the correlation angle of  O(x) with O(H-0 or q~(a-2), 
respectively. In order to realize that, we have to 
find 0}(H-l) (i = 1, 2 , .  ~ . ,  20; j  = 4, 3 , . . . ,  3', 4 )  or 
0}(H-2) (i = 1, 2 . . . .  , 2 0 ; j  = 4, 3 , . . . ,  3', 4'), the 160 
components for the standard vector q~(H-1) or O(H-2), 
respectively [see Eqs. (4) and (6)]. Because the 
abundance for each of  the 20 amino acids in globular 
proteins is known (Nakashima et al., 1986), if we can 
i find p}(I-I-1) or p)(I-I-2), we can immediately obtain 
0}(H-l) or Oj(I-I-2) by means of  Eqs. (5) or (7), respec- 
tively. Actually, p~(I-I-1) or pjffI-2) can be derived from 
a set of  octapeptides known to be cleavable by HIV- 1 
or HIV-2 protease. Such a set of  data is usually termed 
as "training set" or "development set." Below, let us 
first consider the case associated with HIV- 1 protease. 
3.1.  H I V - 1  P r o t e a s e  
In order to compare the predicted results by 
means of the current correlation angle method with 
those by the h probabili ty method, we should use the 
same set of  training data. The following 40 peptide 
sequences, of  which 38 are octapeptides and 2 hepta- 
peptides, have been found cleavable by HIV- I  
protease. In Eq. (14) the arrow indicates the scissile 
bond, which is between the positions P~ and PI'. The 
above 40 peptide sequences were used by the h pro- 
bability method (Poorman et al., 1991) as a training 
set for HIV-1 protease. Using the same training set 
[i.e., Eq. (14)], we can derive pj(H-1) (i = 1, 2, 
• . . ,  20; j = 4, 3 , . . . ,  3', 4'), which, together with 
the abundance of amino acids, are listed in Table I. 
P4 P3 P2 P1 - -  Pv P2" Py P4' 
T Q I M - -  F E T F 
O Q V N - -  Y E E F 
P F I F - -  E E E P 
S F N F - -  P Q I T 
D T V L - -  E E M S 
A R V L - -  A E A M 
A E E L - -  A E I F 
S L N L - -  R E T N 
A T I M - -  M Q R G 
A E C F - -  R I F D 
D Q I L - -  I E I C 
D D L F - -  F E A D 
Y E E F - -  V Q M M 
P I V G - -  A E T F 
T L N F - -  P I S P 
R E A F - -  R V F D 
A E T F - -  Y V D K 
A Q T F - -  Y V N L 
P T L L - -  T E A P 
S F I G - -  M E S A 
D A I N - -  T E F K 
Q I T L - -  W Q R P 
E L E F - -  P E G G 
A N L - -  A E E A 
S Q N Y - -  P I V Q 
P G N F - -  L Q S R 
K L V F - -  F A E 
G D A L - -  L E R N 
K E L Y - -  P L T S 
R Q A N - -  F L G K 
S R S L - -  Y A S S 
A E A M - -  S Q V T 
R K I L - -  F L D G 
G S H L - -  V E A L 
G G V Y - -  A T R S 
F R S G - -  V E T T 
V E V A - -  E E E E 
L P V N - -  G E F S 
E T T A - -  L V C D 
H L V E - -  A L Y L 
(14) 
Based on Table I, for any given octapeptide we 
can calculate its projection angle ®,_~(x) with the 
standard cleavable vector @(H-l) for HIV-1 protease 
according to Eqs. (5) and (10). Thus, according to 
Eq. (11), once the value of 0"_1 is determined, 
AOH.1 (x) is uniquely defined• To realize this, let us 
apply an optimization procedure, which is actually a 
Cleavabi l i ty  of  Pept ide  Sequences  by H I V  Proteases  
Table I. Values of p} Derived from Eq. (14) for Standard Vector ~P(Hq) 
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Amino acid Abundance a Probability of amino acid i at each of eight positions 
Index Code /1 i p~ p~ p~ p~ p~, p~, p~, 
1 A 0.087 7/39 2/40 4/40 2/40 6/40 2/40 4/40 2/39 
2 C 0.016 0/39 0/40 1/40 0/40 0/40 0/40 1/40 1/39 
3 D 0,057 4/39 2/40 0/40 0/40 0/40 0/40 2/40 4/39 
4 E 0.064 2/39 8/40 3/40 1/40 3/40 20/40 5/40 1/39 
5 F 0.039 1/39 3/40 0/40 12/40 5/40 0/40 4/40 4/39 
6 G 0.078 4/39 2/40 0/40 3/40 1/40 0/40 2/40 3/39 
7 H 0.022 1/39 0/40 1/40 0/40 0/40 0/40 0/40 0/39 
8 I 0.052 0/39 2/40 7/40 0/40 1/40 3/40 3/40 0/39 
9 K 0.068 2/39 1/40 0/40 0/40 0/40 0/40 0/40 3/39 
10 L 0.082 1/39 5/40 3/40 12/40 3/40 4/40 0/40 3/39 
11 M 0.021 0/39 0/40 0/40 3/40 2/40 0/40 2/40 2/39 
12 N 0.044 0/39 0/40 6/40 4/40 0/40 0/40 1/40 2/39 
13 P 0.045 4/39 1/40 0/40 0/40 5/40 0/40 0/40 4/39 
14 Q 0.039 1/39 6/40 0/40 0/40 0/40 6/40 0/40 1/39 
15 R 0.048 3/39 3/40 0/40 0/40 3/40 0/40 4/40 1/39 
16 S 0.066 5/39 1/40 2/40 0/40 1/40 0/40 4/40 5/39 
17 T 0.058 2/39 4/40 4/40 0/40 2/40 1/40 5/40 3/39 
18 V 0.070 1/39 0/40 9/40 0/40 3/40 4/40 2/40 0/39 
19 W 0.012 0/39 0/40 0/40 0/40 1/40 0/40 0/40 0/39 
20 Y 0,033 1/39 0/40 0/40 3/40 4/40 0/40 1/40 0/39 
a The values of amino acid abundance in globular proteins are taken from Nakashima et al. (1986). 
compromise between overpredicting for a set of non- 
cleavable peptides and underpredicting for a set of  
cleavable peptides. It is obvious f romEqs .  (11) and 
(12) that if ®H-I is too large, then some noncleavable 
oligopeptides by the enzyme will be overpredicted as 
cleavable. On the other hand, if O*.i is too small, some 
cleavable oligopeptides will be underpredicted as non- 
cleavable. Therefore, to find the optimal value for 
®*-1, two types of  training data are needed: one is of  
cleavable peptide, and the other is of  noncleavable 
peptide. We already have the training data for the 
former (i.e. the 40 oligopeptides listed in Table II). 
The training data for the latter can be obtained as 
follows. It has been found that only three octapeptides 
in calmodulin, i.e. GQVN-YEEF,  YEEF-VQMM, 
and REAF-RVFD,  are cleavable by HIV-1 protease. 
No any other HIV-1 protease cleavage sites whatso- 
ever were detected for calmodulin even after it was 
completely denatured (Poorman et  al., 1991). This 
protein contains 148 residues, and hence can provide 
1 4 8 -  7 = 141 cases for oligopeptides. Excluding 
the above three cleavable peptides, we still have 
141 - 3 = 138 octapeptides, which constitute a set of  
non-cleavable peptides and can be used as a bench- 
mark for checking overpredicted results. The process 
for finding the optimal ®~-1 is illustrated in Fig. 1, 
where the number of correct prediction vs. q~l for the 40 
cleavable oligopeptides is plotted by the dotted line, 
and that for the 138 noncleavable peptides is plotted 
by the dashed line. The solid line indicates the average 
of the two rates. As we can see from Fig. 1, for the 40 
cleavable oligopeptides, the greater the ®*-1, the 
higher the rate of correct predictions; while for the 138 
noncleavable octapeptides, the situation is just the 
opposite. As a combined result of  these two opposite 
changes with ®H-l, there is a peak at ®*-i = 8 2.40 for 
the average of these two rates. Such a value is taken as 
the optimal value for ®*-1 because it leads to the 
highest average rate of  correct predictions. 
The predicted results for the 40 oligopeptides in 
the training set for HIV-1 protease are given in Table 
II. It is shown in that table that there are only three 
octapeptides (i.e., RQAN-FLGK,  ETTA-LVCD, and 
HLVE-ALYL),  whose A®r~.l (x) < 0. This means that, 
except these three, all the other oligopeptides are cor- 
rectly predicted as cleavable because the deviation of 
their characteristic vectors ~(x)  from the standard 
cleavable vector for HIV-1 protease q~(H-1) is within 
the upper limit ®*-1 However, according to the h 
function method (Poorman et  al., 1991) in which the 
criterion for a cleavable peptide sequence is that its h 
value must _>h*0.13, we find that there are eight 
incorrect prediction results. Consequently, the rate of  
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Fig. 1. Plot to show the dependence of the rate of 
corrected prediction on the critical angle ®%: the 
rate of corrected prediction vs. O*_ I for the cleavable 
training set (i.e., the 40 oligopeptides listed in Table 
II) is depicted by the dotted line; the rate of corrected 
prediction vs. ®*~ for the noncleavable training set 
(i.e., the 138 noncleavable octapeptides in cal- 
modulin) is depicted by the dashed line; and an aver- 
age of these two rates is depicted by the solid line. As 
shown by the plot, the larger the ®~_~, the higher the 
rate of corrected prediction for the cleavable peptide 
set (see dotted line), but the lower the rate of 
corrected prediction for the noncleavable peptide set 
(see dashed line). As a consequence, their average 
reaches a maximum (see solid line) at 0% = 82.4 °, 
which is taken as the optimal parameter to predict the 
cleavability by HIV-1 protease according to Eq. (I 1). 
current projection angle method, while only 32/40 = 
80.0% by the h function method. This means that the 
new method has improved the self-consistency in deal- 
ing with the training data set. 
The prediction results for the 34 octapeptides in 
a series of wild-type and mutant proteins (Partin et  al., 
1990) are listed in Table III. Note that although the 
octapeptides listed here are taken from Poorman et  al. 
(1991), any duplicates in either themselves or to the 
octapeptides in the training set of  Table II should be 
excluded. This is because in either the h function 
method or the projection angle method, the sequence 
of an octapeptide is the sole input in predicting its 
cleavability by HIV-protease. Therefore, the total 
countable testing octapeptides in Table III should be 
34 rather than 42. These 34 oligopeptides are outside 
the training set and hence then can be regarded as an 
independent testing set. It is shown in Table III that, 
for these 34 peptides, both methods have 30 correct 
predicted results (i.e., for the testing set selected by the 
authors of the h function method the rate of correct 
prediction for both methods is the same, equal to 
30/34 = 88.2%. 
Blfiha et  al. (1991) have synthesized some analogs 
of  an HIV-1 protease substrate and observed their 
cleavability. A prediction for these peptide sequences 
by the current method and that by the h function 
method are listed in Table IV. As shown from the 
table, for three of  the 11 oligopeptides, the predicted 
results are incorrect if the h function is used. But if 
using the current projection method, only two results 
are incorrectly predicted (i.e., a slightly better result is 
obtained). 
However, if the comparison for independent test- 
ing data is extended to cover more oligopeptides, a 
result in favor of the projection angle method would 
become apparent. According to the recent report by 
Griffiths et  al. (1992), the 20 oligopeptides listed in 
Table V are cleavable by HIV-1 protease. The predicted 
results for these oligopeptides by the current method 
and that by the h function method are also given in 
Table V. As shown from the table, in two of 20 events, 
the results were incorrectly predicted by the h func- 
tion method, meaning the rate of  correct prediction 
was 18/20 = 90.0%. However, if using the current 
sequence-coupled method, none of  them was incor- 
rectly predicted (i.e., a rate of  correct prediction of  
20/20 = 100%!). 
The average accuracy can be obtained by com- 
bining the data in Tables II-V, which turns out to 
be 96/105 = 91.4% for the current method but only 
88/105 = 83.6% for the h function method. This 
indicates that for the same set of data the average 
inaccuracy of the projection angle method is about 
8% higher than that of  the h function method. 
According to statistical mathematics, a normal 
distribution should approximately satisfy the follow- 
ing empirical rule (Mendenhall et al., 1986): 
I M _ S contains approximately 
66% of the predictions 
M _ 2S contains approximately (15) 
95% of the predictions 
M _ 3S contains almost all of  
the predictions 
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Table  II. Predicted Results of  40 Peptide Sequences in Training Set for HIV-1 Protease 
2 9 7  
P4 P3 P2 Pl Pv P2' Py P4' A(~IH.2 (X) (deg) ~' h b Protein 
T Q I M - -  F E T F 16.5 0.97 Actin 
G Q V N - -  Y E E F 17.6 0.96 Calmodulin 
P F I F - -  E E E P 19.6 0.96 pro-ILl-f l  
S F N F - -  P Q I T 10.2 0.92 pol 
D T V L - -  E E M S 18.3 0.90 Autolysis 
A R V L - -  A E A M 19.3 0.89 gag 
A E E L - -  A E I F 19.6 0.89 Troponin  C 
S L N L R E T N 17.4 0.87 Vimentin 
A T I M - -  M Q R G 5.1 0.82 gag 
A E C F - -  R I F D 9.1 0.82 Troponin  C 
D Q I L - -  I E I C 16.7 0.8l Autolysis 
D D L F - -  F E A D 14.9 0.77 pro-ILl-f l  
Y E E F - -  V Q M M 7.0 0.75 Calmodulin 
P I V G - -  A E T F 13.9 0.75 pol 
T L N F - -  P I S P 7.6 0.74 pol 
R E A F - -  R V F D 7.7 0.72 Calmodulin 
A E T F - -  Y V D K 8.4 0.68 plo 
A Q T F Y V N L 7.1 0.58 pol 
P T L L - -  T E A P 13.2 0.57 Actin 
S F I G - -  M E S A 9.8 0.53 Actin 
D A 1 N - -  T E F K 9.9 0.47 Vimentin 
Q I T L W Q R P 4.5 0.46 Autolysis 
E L E F - -  P E G G 12.6 0.46 PE664E 
A N L - -  A E E A 13.2 0.39 PE40 
S Q N Y - -  P I V Q 2.3 0.38 gag 
P G N F - -  L Q S R 5.4 0.38 gag 
K L V F - -  F A E 6.4 0.38 AAP 
G D A L - -  L E R N 11.2 0.33 PE40 
K E L Y - -  P L T S 2.0 0.28 gag 
R Q A N F L G K - 0 . 2  ~' 0.21 gag 
S R S L - -  Y A S S 2.9 0.20 Vimentin 
A E A M - -  S Q v T 1.6 0.17 gag 
R K I L - -  F L D G 3.1 0.12 a pol 
G S H L - -  V E A L 9.0 0.10 a Insulin 
G G V Y - -  A T R S 0.9 0.10 a Vimentin 
F R S G - -  V E T T 5.6 0.09 a gag 
V E V A - -  E E E E 9.7 0.08 a AAP 
L P V N - -  G E F S 8.7 0.08 a AAP 
E T T A - -  L V C D -4 .8"  0.03 a Actin 
H L V E - -  A L Y L - 1.8 ~ 0.02 a Insulin 
aSee Eq. (11), where ®*-i = 82.4° is derived through 
bAccording to the h function method (Poorman et al., 
Otherwise, it cannot  be cleaved by the enzyme. 
Clncorrect prediction by the projection angle method.  
dlncorrect prediction by the h function method.  
the optimization procedure as described in the text. 
1991), an  octapeptide can be cleaved by HIV-1 protease when its h ~> h* = 0.13. 
w h e r e  M a n d  S r e p r e s e n t  m e a n  a n d  s t a n d a r d  d e v i a -  
t i o n  o f  t h e  p r e d i c t e d  q u a n t i t y ,  r e s p e c t i v e l y .  N o w  le t  u s  
s ee  w h a t  d i s t r i b u t i o n  w e  h a v e  f o r  t h e  105 p r e d i c t e d  
r e s u l t s .  B a s e d  o n  t h e  d a t a  l i s t e d  i n  T a b l e s  I I - V ,  i t  is 
f o u n d  t h a t  f o r  A O H .  l ( x )  w e  h a v e :  
' M _ +  S c o n t a i n s  7 0 / 1 0 5  ~ 6 6 %  
o f  t h e  p r e d i c t i o n s  
M _+ 2 S  c o n t a i n s  9 9 / 1 0 5  ~ 9 5 %  
o f  t h e  p r e d i c t i o n s  
M + 3 S  c o n t a i n s  1 0 5 / 1 0 1  = 1 0 0 %  
(i .e . ,  a l l  o f  t h e  p r e d i c t i o n s  
(16)  
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Table II1. Predicted Results for 34 Octapeptides a in Series of Wild-Type and Mutant Proteins (Partin 
et al., 1990) 
P4 P3 P2 Pt - -  Pv P2' P3' /'4' AOn-t (x)(deg) b h" Experimental d 
R Q N Y - -  P I V Q 1.4 e 0.34 g - 
S Q K Y - -  P I V Q -2.2 0.03 - 
S Q Q Y - -  P I V Q -1.4 0.02 - 
s Q N S - -  P I V Q -0.5 0.03 - 
s Q N P - -  P I V Q 0.1 e 0.04 - 
S Q N Y - -  P K V Q - 0 . 1  0 .04  - 
T Q N Y - -  P I V Q 0.5 0.22 + 
S N N Y - -  P I V Q -1.7 e 0.02 y + 
s K N Y - -  P I V Q - 1.6 e 0 .06 f + 
S Q N F - -  P I V Q 7.9 0.68 + 
s Q N Y - -  A I V Q 1.8 0.28 + 
S Q N Y - -  L I V Q 0.1 0.22 + 
S Q N Y - -  T I V Q 0.1 0.16 + 
S Q N Y - -  P V V Q 2.4 0.38 + 
S Q N Y - -  P I I Q 3.4 0.56 + 
S Q N Y - -  P I E Q 4.3 0.63 + 
S Q N Y - -  P I V P 4.1 0.68 + 
S Q N Y - -  P I V E 1.6 0.28 + 
S F N F - -  P Q I T 10.2 0.92 + 
T F N F - -  P Q I T 8.4 0.84 + 
Y F N F - -  P Q I T 8.4 0.82 + 
S C N F - -  P Q I T 8.8 0.75 + 
S Y N F - -  P Q I T 8.4 0.53 + 
S F T F - -  P Q I T 8.5 0.85 + 
S F Y F - -  P Q I T 6.6 0.39 + 
S F N S - -  P Q I T 1.8 0.12 f + 
S F N Y - -  P Q I T 4.5 0.77 + 
S F N Y - -  G Q I T 6.7 0.57 + 
S F N Y - -  L Q I T 7.9 0.79 + 
S F N Y - -  P P I T 6.1 0.29 + 
S F N Y - -  P L I T 7.8 0.78 + 
S F N Y - -  P Q v T 9.1 0.85 + 
S F N Y - -  P Q D T 9.4 0.87 + 
S F N Y - -  P Q I I 8.3 0.52 + 
a Octapeptides listed here are taken from Table 10 of Poorman et al. (1991). However, any duplicates, 
either to the octapeptides in the training set or to those in that table itself, are excluded. Therefore, the 
total testing octapeptides here should be 34 rather than 42. 
b See footnote a to Table II. 
c See footnote b to Table If. 
+ or - represents cleavable or noncleavable by HIV-1 protease. 
e Incorrect prediction by the correlation angle method. 
Qncorrect prediction by the h probability method. 
w h i c h  is ve ry  c lose  to  t he  e m p i r i c a l  ru le  fo r  the  n o r m a l  
d i s t r i b u t i o n  as  d e s c r i b e d  by  Eq .  (15). H o w e v e r ,  fo r  the  
f u n c t i o n  h as  u s e d  by  P o o r m a n  et al. (1991), we  
i n s t e a d  h a v e  
{ M ~ S  c o n t a i n s  56/105 ~ 5 3 %  o f  t he  p r e d i c t i o n s  (17) M _  2 S  c o n t a i n s  1051101 = 100% 
o f  t he  p r e d i c t i o n s  
w h i c h  c o m p l e t e l y  v io la t e  t he  e m p i r i c a l  ru le  o f  Eq .  
(15), m e a n i n g  t h a t  t he  p r e d i c t e d  resu l t s  b a s e d  o n  the  
h f u n c t i o n  m e t h o d  a re  s ign i f ican t ly  d i s t o r t e d  f r o m  the  
n o r m a l  d i s t r i b u t i o n .  Th is  m i g h t  be  c a u s e d  by  the  a rb i -  
t r a r y  a s s i g n m e n t  fo r  p a r a m e t e r s  in the  h f u n c t i o n  
m e t h o d ,  as  d i s c u s s e d  a t  t he  b e g i n n i n g  o f  th is  p a p e r .  
Espec i a l ly  w h e n  the  t r a i n i n g  d a t a  a re  l imi ted ,  t he  
a r b i t r a r y  a s s i g n m e n t  m i g h t  af fect  t he  ob jec t ive  n a t u r e  
o f  t he  p r e d i c t e d  resul ts .  
3 . 2 .  H I V - 2  P r o t e a s e  
A g a i n ,  fo r  f ac i l i t a t ing  c o m p a r i s o n ,  t he  t r a i n i n g  
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set used in the h function method (Poorman et al., 
1992) for HIV-2 protease was used here. The set con- 
sists of  22 oligopeptides, with 21 octapeptides and one 
heptapeptide. Thus, similar to Eq. (14) for the case of  
HIV-1 protease, we also have the following equation 
for HIV-2 protease: 
P4 P3 P2 P~ - -  Pv P2' Py 
S Q N Y - -  P I V 
E E E L - -  A E C 
T Q I M - -  F E T 
G Q V N - -  Y E E 
G G N Y - -  P V Q 
A E E L - -  A E I 
P F A A - -  A Q Q 
R Q v L - -  F L E 
A T I M - -  M Q R 
S L N L - -  P V A 
A N L - -  A E E 
P T L L - -  T E A 
S F I G - -  M E S 
Y E E F - -  V Q M 
R H V M - -  T N L 
Y I S A - -  A E L 
G L A A - -  P Q F 
D G N G - -  T I D 
G D A L - -  L E R 
N P T E - -  A E L 
R Q A G - -  F L G 






















2Note that there is an error in the paper by Poorman et al. (1991); 
that is, this sequence was mistakenly counted as "TQIM-FETP." 
where the arrow indicates the scissile bond by HIV-2 
protease. According to Eq. (18), we can derived 
pj(H-2) (i = 1, 2, . . . ,  20; j = 4, 3 . . . . .  3', 4'), which, 
together with the abundance of amino acids, are listed 
in Table VI. 
Thus, for any given octapeptide, we can calculate 
its projection angle On.2(x) with the standard cleav- 
able vector ~(I+2) for HIV-2 according to Eqs. (6) and 
(10). The critical angle O* for which we used the same 
optimization procedure as described above in finding 
the critical angle O* for HIV-1 protease thus remains 
to be determined. Now the training data for the cleav- 
able set were taken from the 22 oligopeptides in Table 
VI. But the training data for the noncleavable set were 
taken from the 139 octapeptides along the calmodulin 
sequence. This is because that, except G E V N - Y E E F  
and YEEF-VQMM,  no other HIV-2 cleavage sites 
whatsoever were detected for calmodulin even after it 
was completely denatured (Poorman et al., t991). 
l 'herefore, its 1 4 8 -  7 -  2 = 139 octapeptides can 
serve as a benchmark for HIV-2 protease in checking 
overpredicted results. The process of  optimal pro- 
cedure is illustrated in Fig. 2, f rom which we find 
OH~.2 = 76.2 °. 
By setting such a value for 0*.2 to predict the 139 
noncleavable octapeptides taken from the sequence of 
calmodulin, 124 were found to have negative values of  
AOH_2(x), meaning the rate of  correct prediction is 
89% within the noncleavable training set. The pre- 
dicted results for the 22 cleavable oligopeptides in the 
HIV-2 protease training set are listed in Table VII. 
There, the values of  AOI_I. 2 (X) are all greater than zero, 
1 1 0  - 
~ "  1 0 0  - 
O 
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Fig. 2. Plot to show the dependence of the rate of 
corrected prediction on the critical angle ®~-2: the 
rate of corrected prediction vs. ®~-2 for the cleavable 
training set (i.e., the 22 oligopeptides listed in Table 
VII) is depicted by the dotted line; the rate of corrected 
prediction vs. ®~-2 for the noncleavable training set 
(i.e., the 139 noncleavable octapeptides in cap 
modulin) is depicted by the dashed line; and an aver- 
age of these two rates is depicted by the solid line. As 
shown by the plot, the larger the ®~-2, the higher the 
rate of corrected prediction for the cleavable peptide 
set (see dotted line), but the lower the rate of 
corrected prediction for the noncleavable peptide set 
(see dashed line). As a consequence, their average 
reaches a maximum (see solid line) at ®~-2 = 76.2°, 
which is taken as the optimal parameter to predict the 
cleavability by HIV-2 protease according to Eq. (11). 
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Table IV. Predicted Results for Synthesized Analogs of HIV-1 Protease Substrate a 
P4 P3 P2 Pi - -  Pv Pz Pr  P4, AOn-l(x)(deg) b h c Hydrolysis d 
S Q N Y - -  P I V Q 2.3 0.38 + 
S Q N Y - -  P A V Q 0.7 0.20 + 
S Q N Y - -  P N V Q 0.6 0.06: + 
S Q N Y - -  P F V Q 0.7 0.06 f + 
S Q N Y - -  P L V Q 2.1 0.34 + 
S Q N Y - -  P V V Q 2.4 0.38 + 
S Q N Y - -  P G V Q -0.3 0.03 - 
S Q N Y - -  P D v Q 0.2 e 0.05 - 
S Q N Y - -  P K V Q -o.1 0.04 - 
S Q N Y - -  A I V Q 1.8 e 0.28.: - 
S Q N Y - -  D I V Q -1.2 0.02 - 
S Q N Y - -  K 1 V Q -1.5 0.02 - 
a Octapeptides listed here are taken from BlS.ha et al. (1991), where peptides with relative activity <0.0l 
are of resistance to HIV-1 protease (i.e. not cleaved). 
b See footnote a to Table II. 
c See footnote b to Table 11. 
a + and - refer to processing by, or resistance to, HIV-1 protease (B1/tha et al., 1991). 
elncorrect prediction by the projection angle method. 
:incorrect prediction by the h function method (Poorman et al., 1991). 
m e a n i n g  t h a t  all t he  22 o l i g o p e p t i d e s  c a n  be  c l eav ed  
by  H I V - 2  p r o t e a s e - - n a m e l y ,  t he  m e t h o d  is ful ly self- 
c o n s i s t e n t  w i t h i n  t he  c l eavab le  t r a i n i n g  set.  H o w e v e r ,  
u s ing  the  h f u n c t i o n  m e t h o d ,  it  w a s  f o u n d  t h a t  t he  
o c t a p e p t i d e s  N P T E - A E L Q  a n d  R Q A G - F L G Q  w e r e  
i n c o r r e c t l y  p r e d i c t e d  as n o n c l e a v a b l e  (Tab l e  VII ) .  
T h e  c u r r e n t  m e t h o d  w a s  f u r t h e r  u s e d  to  p r e d i c t  
the  c l eavab l e  si tes in ac t in  by  H I V - 2  p r o t e a s e .  T h e  
ac t in  s e q u e n c e  c o n t a i n s  377 r e s idues  a n d ,  hence ,  
p o s s e s s e s  3 7 7 -  7 = 370 o c t a p e p t i d e  s equences .  O f  
these  s equences ,  on ly  T Q I M - F E T F ,  P T L L - T E A P ,  
a n d  S F I G - M E S A  are  c l eavab le  by  H I V - 2  p r o t e a s e  
( P o o r m a n  e t  al . ,  1991). T h u s ,  t he  r e m a i n i n g  367 
o c t a p e p t i d e s  f o r m  a n o n c l e a v a b l e  set  w h i c h  is o u t s i d e  
the  a b o v e  t r a i n i n g  set  d a t a  a n d  h e n c e  c a n  serve  as an  
i n d e p e n d e n t  set  to  tes t  t he  p r e d i c t e d  resul ts .  I t  h a s  
Table V. Predicted Results for 15 Oligopeptides Cleavable by HIV-I Protease as Observed Recently 
(Grifiths et al., 1992) 
P4 P3 P2 P1 - -  Pv Pz' P3' P4" A®n-I(x)(deg) a hb Hydroly sisc 
A R V L - -  F E A L 18.9 0.85 + 
A R V L - -  F Q A L 10.1 0.74 + 
A R V L - -  F I A L 7.8 0.51 + 
A R V L - -  F V A L 8.0 0.51 + 
A R V L - -  F A A L 6.3 0.29 + 
A R V L - -  F D A L 5.8 0.07 d + 
A R V L - -  F N A L 6.1 0.09 a + 
A R V L - -  F T A L 6.4 0.24 + 
A R N L - -  F E A L 17.6 0.86 + 
A R V Y - -  P E A L 13.9 0.75 + 
A R N Y - -  P E A L 12.6 0.76 + 
S Q N Y - -  P I V 2.5 0.49 + 
S Q N F - -  P I V Q 7.8 0.67 + 
S Q N Y - -  P I V L 2.4 0.46 + 
A Q N Y - -  P I V L 3.2 0.48 + 
a See footnote a to Table II. 
b See footnote b to Table II. 
" + Refers to processing by HIV-1 protease. 
d Incorrect prediction by the h function method. 
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Table  VI. Values ofpj Derived from Eq. 18 for Standard Vector • (H-2) 
Amino acid Abundance ° Probability of amino acid i at each of 8 positions 
i Code f P~ P~ Pl Pil fv  P~' P~' P~' 
1 A 0.087 2/21 1/22 4/22 3/22 6/22 0/22 3/22 2/22 
2 C 0.016 0/21 0/22 0/22 0/22 0/22 0/22 1/22 0/22 
3 D 0.057 1/21 1/22 0/22 0/22 0/22 0/22 1/22 0/22 
4 E 0.064 1/21 3/22 3/22 1/22 0/22 10/22 3/22 0/22 
5 F 0.039 0/21 2/22 0/22 2/22 3/22 0/22 1/22 5/2U 
6 G 0.078 4/21 2/22 0/22 3/22 0/22 0/22 1/22 2/22 
7 H 0.022 0/21 1/22 0/22 0/22 0/22 0•22 0/22 1/22 
8 I 0.052 0/21 1/22 3/22 0•22 0/22 2•22 1/22 0/22 
9 K 0.068 0/21 0/22 0/22 0/22 0/22 0/22 0/22 2/22 
10 L 0.082 0/21 2/22 1/22 7/22 1/22 2/22 3/22 1/22 
11 M 0.021 0/21 0/22 0/22 3/22 2/22 0/22 1/22 1/22 
12 N 0.044 1/21 0/22 6/22 1/22 0/22 1/22 0/22 1/22 
13 P 0.045 3/21 1/22 0/22 0/22 5/22 0/22 0/22 1/22 c 
14 Q 0.039 0/21 5/22 0/22 0/22 0/22 4/22 2/22 3/22 
15 R 0.048 3/21 1/22 0/22 0/22 0/22 0/22 2/22 2/22 
16 S 0.066 3/21 0/22 1/22 0/22 0/22 0/22 1/22 1/22 
17 T 0.058 1/21 2/22 1/22 0/22 3/22 0/22 1/22 0/22 
18 V 0.070 0/21 0/22 3/22 0/22 1/22 3/22 1/22 0/22 
19 W 0.012 0/21 0/22 0/22 0/22 0/22 0/22 0/22 0/22 
20 Y 0.033 2/21 0/22 0/22 2/22 1/22 0/22 0/22 0/22 
"The values of amino acid abundance in globular proteins are taken from Nakasgima et at. (1986). 
Table  VII. Predicted Results for 22 Oligipeptides in Training Set for HIV-2 Protease 
P4 P3 P2 Pt - -  Pt' P2' P3' P4' A•H_2 (x) (deg) a h b Protein 
S Q N Y - -  P I V Q 17.2 0.95 gag 
E E E L A E C F 31.2 0.95 c Troponin C 
T Q I M - -  F E T F c 25.6 0.86 C Actin 
G Q V N - -  Y E E F 25.2 0.93 c Calmodulin 
G C N Y - -  P V Q H 12.9 0.90 gag 
P R N F - -  P V A Q 14.2 0.90 gag 
A E E L - -  A E I F 30.6 0.90 c Troponin C 
P F A A - -  A Q Q R 12.1 0.86 gag 
R Q V L - -  F L E K 14.9 0.85 pol 
A T I M - -  M Q R G 4.3 0.84 gag 
S L N L - -  P V A K 18.3 0.83 pol 
A N L - -  A E E A 27.2 0.72 PE40 
P T L L - -  T E A P 17.4 0.53" Actin 
S F I G - -  M E S A 12.0 0.67 Actin 
Y E E F - -  V Q M M 1.2 0.63 Calmodulin 
R H V M T N L G 2.0 0.59 Calmodulin 
Y I S A - -  A E L R 13.7 0.43 Calmodulin 
G L A A - -  P Q F S 6.8 0.40 pol 
D G N G - -  T I D F 7.1 0.45 C Calmodulin 
G D A L - -  L E R N 16.6 0.33 PE40 
N P T E - -  A E L Q 11.5 0.24 d Calmodulin 
R Q A G - -  F L G L 3.0 0.24 d gag 
~'See Eq. (1 I), where ®*-2 = 76.2° is derived through the optimization procedure as illustrated by Fig. 2. 
h According to the h function method, a peptide can be cleaved by HIV-2 protease when its h /> h* = 0.25. Otherwise, it cannot be cleaved 
by the enzyme. 
"Correction has been made here for the error found in the original Table 6 of Poorman et al. (1991) as indicated by the footnote in Eq. 
18. This will affect the h values of those oligopeptides whose residues at the P4, subsite are P or F. 
Jlncorrect prediction by the h function method. 
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been found that, of  the 367 noncleavable octapeptides, 
350 have negative values of  AOH_2(x), meaning the 
rate of  correct prediction is 350/367 = 95%. 
4. C O N C L U S I O N  
Octapeptides formed by 20 amino acids may 
form 208 = 2.56 x 101° different sequences. What  kind 
of  sequences can, and what kind of sequences cannot, 
be cleaved by HIV protease is a very important  pro- 
blem in designing effective HIV protease 
inhibitors as potential drugs for AIDS therapy. In 
view of  this, a new method, the so-called projection 
angle method, is developed to predict the cleavability 
of  a peptide sequence by HIV-1 or HIV-2 protease. 
The average predicted accuracy by the new method 
for the 105 peptide sequences whose cleavability is 
known to HIV-1 protease is 91.4%, which is about  
8% higher than that of  the existing h function method 
(Poorman et  al., 1991) for the same set of  peptide 
sequences. A considerably high rate of  correct predic- 
tion was also obtained when the new method was used 
to predict HIV-2 protease-cleaved sites in some pro- 
teins, although we still lack a sufficiently large cleav- 
able training data set for HIV-2 protease. Moreover,  
the higher predicted rate is reflected by dealing with 
both the training set and testing set, indicating that the 
current method bears an improved feature in both 
self-consistency and extrapolating-effectiveness. 
Besides, the predicted results by the new method as- 
sume a normal  distribution, but, the predicted results 
by the h function method do not, indicating that the 
new method is more reasonable than the previous one 
from the viewpoint of  probabili ty theory. It  is expect- 
ed that, with the accumulation of  more experimental 
data on the cleavability of  peptides by HIV protease, 
a better training set data can be established, and an 
even higher rate of  prediction by the new method can 
be obtained. In view of  this, the new method may be 
quite useful in the search for effective inhibitors of  
HIV protease, which is an important  procedure in 
designing potential drugs for AIDS therapy. 
REFERENCES 
Barr6-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., 
Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., V6zinet- 
Brun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. 
(1983). Science 220, 868-871. 
Blfiha, I., Nemec, J., T6zs~r, J., and Oroszlan, S. (1991). Int. J. 
Peptide Protein Res. 38, 453-458. 
Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., 
Kaplan, M., Haynes, B. F., Palker, T. J., Redfield, R., Oleske, 
J., Safai, B., White, G., Foster, P., and Markham, P. D. (1984). 
Science 224, 500-503. 
Griffiths, J. T., Phylip, L. H., Konvalinka, J., Strop, P., Gustchina, 
A., Wlpdawer, A., Davenport, R., Briggs, R., Dunn, B. M., 
and Kay, J. (1992). Biochemistry 31, 5193-5200. 
Hellen, C. U. T., Kr/iusslich, H. G., and Wimmer, E. (1989). Bio- 
chemistry 28, 9881-9890. 
Henderson, L. E., Benveniste, R. E., Sowder, R. C., Copeland, 
T. D., Schutz, A. M., and Oroszlan, S. (1988). J. Virol. 62, 
2587-2595. 
Kohl, N. E., Emini, E. A., Schlief, W. A., Davis, L. J., Heimbach, 
J., Dixon, R. A. F., Scolnik, E. M., and Sigal, I. S. (1988). Proc. 
Natl. Sci. USA 85, 4686-4690. 
Mendenhall, W., Scheaffer, R. L., antl Wackerly, D. D. (1986). 
Mathematical Statistics with Applications, Chap. 1, pp. 7-10. 
Nakashima, H., Nishikawa, K., and Ooi, T. (1986). J. Biochem. 99, 
152-162. 
Partin, K., Krgusslich, H. G., Ehrlich, L., Wimmer, E., and Carter, 
C. (1990). J. Virol. 64, 3938-3947. 
Poorman, R. A., Tomasselli, A. G., Heinrikson, R. L., and K4zdy, 
F. J. (1991). J. Biol. Chem. 266, 14,554-14,561. 
Putney, S. (1992). TIBS 17, 191-196. 
Schechter, I. and Borger, A. (1967) On the size of the active site in 
proteases. J. Pain. Biochem. Biophys. Res. Com. 27, 157-162. 
Wlodawer, A., Miller, M., Jask61ski, M., Sathyanarayana, B. K., 
Baldwin, E., Weber, I. T., Selk, L. M., Clawson, L., Schneider, 
J., and Kent, S. B. H. (1989). Science 245, 616-621. 
